TL 118 - Teligene US
Alternative Names: TL-118; TL118-Teligene USLatest Information Update: 29 Sep 2023
At a glance
- Originator Teligene US
- Class Antineoplastics; Nonsteroidal anti-inflammatories; Small molecules; Sulfonamides
- Mechanism of Action Tropomyosin-related kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 24 Aug 2023 Preclinical trials in Solid tumours in USA (PO) prior to August 2023 (NCT06010342)
- 24 Aug 2023 Teligene US plans a phase II trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in unknown location (PO, Capsule) in January 2024 (NCT06010342)
- 13 Jan 2023 Teligene US has patent granted for substituted pyrazolopyrimidines useful as kinases inhibitors in Finland, Japan, China, Spain, Europe and USA